HRG
HRG (histidine-rich glycoprotein, also known as HRGP or HPRG) is a secreted plasma glycoprotein that acts as an adapter, binding heme, heparin, thrombospondin, plasminogen and divalent metal ions. It is linked to angiogenesis, coagulation, fibrinolysis and immune clearance. Browse Assay Genie's current range of HRG research reagents below, or read on for the biology behind the target.
HRG is a plasma glycoprotein that binds a wide range of ligands, including heme, heparin, heparan sulfate, thrombospondin, plasminogen and divalent metal ions. Its binding to heparin and heparin/glycosaminoglycans is zinc-dependent, and it binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Acting as an adapter protein, HRG is implicated in immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis.
In immune handling, HRG binds IgG subclasses containing kappa and lambda light chains, regulating their clearance and inhibiting the formation of insoluble immune complexes. It also enhances phagocytosis of necrotic cells through a heparan sulfate-dependent pathway, which can be modulated by ligands such as heparin and zinc ions. HRG tethers plasminogen to the cell surface, binds T-cells and alters their morphology, and inhibits rosette formation. In angiogenesis it blocks the CD6-mediated antiangiogenic effect of thrombospondins THBS1 and THBS2, and it regulates VEGF signalling by reducing VEGF-induced PXN/paxillin and ILK complex formation and focal adhesion kinase and alpha-actinin tyrosine phosphorylation, thereby limiting endothelial cell motility. It also contributes to tumour angiogenesis and immune surveillance, normalising tumour vessels and polarising tumour-associated macrophages.
The HRG gene encodes a protein with two cystatin-like domains, found in plasma and platelets, and belongs to the HGNC group of type 4 cystatins. A peptide from the protein shows antimicrobial activity against C. albicans, E. coli, S. aureus, P. aeruginosa and E. faecalis. Inhibition of fibrinolysis and reduced inhibition of coagulation suggest a potential prothrombotic effect, and mutations in the gene cause thrombophilia associated with abnormal HRG levels. Mouse and rat orthologs are both named Hrg.
HRG modulates angiogenesis by blocking thrombospondin effects via CD6 and by regulating VEGF-induced signalling in endothelial cells.
HRG tethers plasminogen, inhibits fibrinolysis and reduces inhibition of coagulation, and gene mutations cause thrombophilia.
HRG normalises tumour vessels and polarises tumour-associated macrophages, linking it to tumour angiogenesis, immune surveillance and metastasis.
HRG binds IgG and heparan sulfate, regulating clearance of immune complexes, pathogens and necrotic cells.
HRG is a secreted plasma adapter protein that binds heme, heparin, heparan sulfate, thrombospondin, plasminogen and metal ions. It is implicated in immune complex and pathogen clearance, chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis, and it regulates VEGF signalling in endothelial cells.
HRG stands for histidine-rich glycoprotein, and it is also written HRGP or HPRG. UniProt lists the protein as histidine-rich glycoprotein, and HGNC places the gene in the type 4 cystatin group because the protein contains two cystatin-like domains.
Mouse and rat each have an ortholog named Hrg. In humans, mutations in the HRG gene lead to thrombophilia due to abnormal HRG levels. Check the datasheet of any product for its validated reactivity.
Thrombospondins, plasminogen, VEGF pathway components and other partners of HRG with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P04196; product specifications from Assay Genie datasheets.